Genzyme Recognizes International Rare Disease Day with Global Awareness Programs and Launch of Third Annual Patient Advocacy

  Genzyme Recognizes International Rare Disease Day with Global Awareness
  Programs and Launch of Third Annual Patient Advocacy Leadership (PAL) Awards

Business Wire

CAMBRIDGE, Mass. -- February 28, 2013

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced its
support of International Rare Disease Day with a series of initiatives meant
to call attention to rare diseases as an important public health issue and to
improve rare disease education, research, and treatment. Observed annually on
the last day of February, Rare Disease Day is an international awareness
campaign organized by the patient organization EURORDIS and supported by
hundreds of other patient organizations around the world.

February 28, 2013 marks the sixth International Rare Disease Day. This year’s
theme, “Rare Disorders without Borders,” emphasizes that international
cooperation is essential for fighting diseases that affect only a few people
in each country and for which expertise is scarce and scattered. In
celebration of this theme, Genzyme is pleased to launch a new website
highlighting collaborative activities taking place globally to recognize Rare
Disease Day:

Genzyme sites around the world are partnering with local patient organizations
on a variety of Rare Disease Day activities meant to educate policymakers,
medical professionals, patients and caregivers, and the general public and
empower them to advocate for those affected by rare diseases. These
initiatives include:

  *Rare Disease Day running/cycling relay connecting Genzyme sites in
    Naarden, the Netherlands; Waterford, Ireland; and four Massachusetts
  *Launch of “Facing Fabry Together,” a film that tells the stories of
    families from France, Germany, Brazil, and Canada that are each living
    with Fabry disease. Visit to watch the film
  *Family forum held in Singapore for rare disease patients and their
    families, friends, and caregivers
  *Comic book art contest meant to share real-life stories of people living
    with Mucopolysaccharidoses (MPS) in Hong Kong
  *Rare disease symposium held in Russia for policymakers and the public
  *Documentary film project about individuals with rare diseases filmed in
  *“Roads & rails” public awareness campaign, displaying rare disease
    information on highly trafficked roads and train stations in France
  *Spain’s “Esperanza” (hope) product line, including mugs, bracelets, key
    chains, magnets, and other materials designed to allow people to express
    solidarity with those living with rare diseases
  *Chile’s event to empower children with rare diseases to paint
    self-portraits and share their paintings with policymakers
  *Art exhibition in Italy featuring paintings, photos, videos, and
    theatrical performances created by rare disease patients and advocates
  *20 events in Brazil, including a walk in Sao Paulo, a bike ride in Recife
    City, and the launch of an educational illustrated book on Gaucher disease

In addition, Genzyme is pleased to announce the launch of the third annual
Patient Advocacy Leadership Awards (PAL Awards), a global grant program
supporting non-profit patient organizations that work on behalf of individuals
living with lysosomal storage disorders (LSDs), a group of rare, inherited
disorders that cause progressive and debilitating health problems. Grants are
awarded through a competitive process to organizations that seek funding for
innovative programs and projects that improve disease awareness, patient care
and support, and education. In 2012, more than 50 patient organizations
representing 27 countries submitted proposals, and nine winners chosen by an
external review committee received a total of $100,000 from Genzyme.

“Promoting understanding of the journey of those affected by rare diseases
while advancing therapies and scientific innovation are core to who Genzyme
is, and it is an honor to partner today with advocacy organizations globally
to recognize Rare Disease Day,” said Jamie Ring, Genzyme’s Vice President of
Global Patient Advocacy for Rare Diseases. “As we begin the PAL Award process
again this year, we look forward to seeing how this program can be utilized to
support the evolving needs of rare disease advocacy leaders around the world.
Together, we recognize that there is still great work – and opportunity –
ahead of us.”

More About Genzyme Patient Advocacy Leadership (PAL) Awards
Organizations may apply for a Genzyme PAL Award for programs that support
lysosomal storage disorder awareness, advocacy on behalf of patient
communities, patient education and patient care, support and communication
networks. This grant program is supplemental to Genzyme’s existing grants
program and will not replace the contributions made locally each year to
support advocacy groups. Proposals will be reviewed by an external review
committee. Applications must be received by June 7, 2013 and the award
recipients will be announced by September 30, 2013. For more information on
the Genzyme PAL Awards program, or to apply for a grant, please visit

About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies
for patients affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the compassion and
commitment of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the lives of the
patients and families we serve. That goal guides and inspires us every day.
Genzyme’s portfolio of transformative therapies, which are marketed in
countries around the world, represents groundbreaking and life-saving advances
in medicine. As a Sanofi company, Genzyme benefits from the reach and
resources of one of the world’s largest pharmaceutical companies, with a
shared commitment to improving the lives of patients. Learn more at

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).


Media Contact:
Jessica Colund, 617-768-4477
Press spacebar to pause and continue. Press esc to stop.